*Applications will be reviewed on a rolling-basis.
A research opportunity is available in the Office of New Drugs, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
Sunscreen products contain UV-filters as active ingredients for the protection of skin against UV radiation. Dermal absorption data reveals systemic exposure of UV-filters in humans, which can be obtained from clinical maximal usage trials (MUsT). FDA guidance recommends conducting in vitro skin permeation tests (IVPT) to help select formulations for the clinical MUsT, as IVPT results may be indicative of in vivo absorption. We aim to develop sensitive and robust IVPT methods which are not available in the literature. In addition, different skin membranes will be used and the most appropriate model will be selected and validated.
Under the guidance of a mentor, the participant will learn to develop and validate methodologies for safety and quality evaluation of sunscreen products. Correlations between the in vitro and in vivo performance of the sunscreen products will be investigated with the help of modeling and prediction software.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity (FDA-CDER-2021-0621) in your email.